CLINICAL TRIALS PROFILE FOR PULMICORT FLEXHALER

All Clinical Trials for PULMICORT FLEXHALER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00702325 ↗	Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans	Completed	AstraZeneca	Phase 4	2008-06-01	To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma.
NCT01218399 ↗	Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations	Completed	AstraZeneca	N/A	2009-09-01	This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone.
NCT01218399 ↗	Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations	Completed	Stanford University	N/A	2009-09-01	This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone.
NCT01219738 ↗	Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide	Completed	AstraZeneca	N/A	2008-07-01	Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists).
NCT01219738 ↗	Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide	Completed	University of Miami	N/A	2008-07-01	Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists).
NCT01520688 ↗	Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth	Completed	West Penn Allegheny Health System	Phase 4	2012-02-01	Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller. Inhaled corticosteroids are the standard treatment for mild peristent asthma. The purpose of this study is to measure children rate of growth while on different inhaled corticosteroids.
NCT02357277 ↗	The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton	Withdrawn	Columbia University	Phase 4	2015-03-01	There are over 10 million individuals with asthma using inhaled glucocorticoids (IGCs) in the United States. While oral GCs are recognized to have destructive skeletal effects, far less is known about the effects of IGCs. This gap in our knowledge is of critical importance, not only because of the prevalence, chronic nature and long duration of IGC use, but also because several studies have found that patients using IGCs are at increased risk of fracture. Fracture risk is greatest in postmenopausal (PM) women, in whom IGCs may augment negative effects of estrogen loss and aging. The investigators hypothesize that initiation of IGCs in IGC naïve PM women will lead to decreased bone formation and uncoupling of bone turnover, a potential mechanism for the effect of IGCs on the skeleton. To test our hypothesis, the investigators will perform a randomized, controlled 4 week study of the acute effects of commonly used doses of budesonide (360 or 720 mcg) on bone turnover and circulating osteoblast precursors in 60 treatment naïve, non-asthmatic, PM women. These studies are of high clinical significance because there are currently no guidelines regarding screening, prevention or treatment for osteoporosis in patients using IGCs, nor is IGC use taken into account when calculating fracture risk in PM women, the group at highest risk of fracture. High quality evidence for low volumetric bone mineral density (BMD) and abnormal bone quality in PM women using IGCs has the potential to change clinical practice by supporting specific interventions to prevent bone loss and fractures.

Clinical Trial Conditions for PULMICORT FLEXHALER

Condition Name

Condition Name for PULMICORT FLEXHALER
Intervention	Trials
Asthma	4
Osteoporosis	1
Relative Bioavailability	1

Condition MeSH

Condition MeSH for PULMICORT FLEXHALER
Intervention	Trials
Asthma	4
Osteoporosis	1

Clinical Trial Locations for PULMICORT FLEXHALER

Trials by Country

Trials by Country for PULMICORT FLEXHALER
Location	Trials
United States	27

Trials by US State

Trials by US State for PULMICORT FLEXHALER
Location	Trials
Pennsylvania	2
New York	2
Maryland	2
Florida	2
California	2

Clinical Trial Progress for PULMICORT FLEXHALER

Clinical Trial Phase

Clinical Trial Phase for PULMICORT FLEXHALER
Clinical Trial Phase	Trials
Phase 4	3
Phase 1	1
N/A	2

Clinical Trial Status

Clinical Trial Status for PULMICORT FLEXHALER
Clinical Trial Phase	Trials
Completed	5
Withdrawn	1

Clinical Trial Sponsors for PULMICORT FLEXHALER

Sponsor Name

Sponsor Name for PULMICORT FLEXHALER
Sponsor	Trials
AstraZeneca	4
University of Miami	1
West Penn Allegheny Health System	1

Sponsor Type

Sponsor Type for PULMICORT FLEXHALER
Sponsor	Trials
Other	4
Industry	4

Last updated: May 11, 2026

PULMICORT FLEXHALER (budesonide) | Clinical Trials Update and Market Outlook

Pulmicort Flexhaler is a budesonide inhaled corticosteroid (ICS) for asthma maintenance and for prevention of symptoms, marketed in the US as a prescription inhalation powder device. The drug’s active ingredient is an established product class, and the key commercial dynamics in the near term are dominated by (1) generic and payer pressure on an older molecule, (2) competitor share shifts within ICS and ICS/LABA classes, and (3) device and formulary access rather than new-ingredient pipeline risk.

This update focuses on what materially drives clinical evidence and commercial demand for the Flexhaler product label versus broader budesonide ICS market substitutes.

---

What is the current clinical development status for Pulmicort Flexhaler?

Is there active, label-relevant late-stage development?

No new, publicly disclosed late-stage (Phase 3 or Phase 4 with registrational intent) clinical development program for Pulmicort Flexhaler specifically is evident in major trial registries and regulatory update streams in the current cycle. The clinical evidence base for budesonide ICS products primarily reflects older trial generations and ongoing post-marketing safety and effectiveness surveillance, which typically does not generate new regulatory label expansions at pace.

What is the clinical role supported by existing evidence?

The clinical rationale for budesonide ICS in asthma management is well established. In practice, Pulmicort Flexhaler functions as:

• Controller therapy for persistent asthma to reduce inflammation and prevent symptoms.
• A low-to-medium dose ICS option within stepwise asthma treatment algorithms.

What do trial populations and endpoints historically emphasize for ICS?

Across budesonide ICS literature, the recurring endpoint framework is:

• Lung function (FEV1, peak expiratory flow)
• Symptom control (daytime/nighttime symptoms, rescue use)
• Exacerbations (rates and time to first exacerbation)
• Safety (oral candidiasis, dysphonia, growth velocity in pediatric cohorts)

---

Which trials matter for decision-making now?

What is the practical “update” investors should use?

For market projection and risk modeling, the operational “trial update” is not new chemistry but rather whether any current evidence trends change utilization patterns. For older ICS molecules like budesonide, that usually happens through:

• real-world comparative effectiveness (RWE) across devices and competitors,
• guideline updates affecting ICS dosing strategies,
• payer formularies favoring specific devices, strengths, and copay tiers.

Where RWE typically lands for budesonide ICS products

Budesonide ICS products compete on:

• adherence by device usability,
• payer access,
• and switching behavior between ICS monotherapy and ICS/LABA combinations.

Clinical trials in this category rarely overturn baseline efficacy expectations; they more often inform relative adherence and exacerbation reduction under real-world conditions.

---

How does Pulmicort Flexhaler fit the asthma controller market?

What drug class drives the market?

Pulmicort Flexhaler is an ICS. The controller category is segmented across:

• ICS monotherapy (patients on step 2 and selected step 3)
• ICS/LABA for broader controller coverage as disease severity increases
• SABA rescue for acute symptoms (outside controller category)

This segmentation matters because patients often move up the step ladder over time, shifting demand toward ICS/LABA and away from pure ICS, unless budget constraints force continued ICS use.

---

Market analysis: current demand drivers and headwinds

What are the main demand drivers?

Key demand drivers for an older budesonide ICS include:

• ongoing asthma prevalence and maintenance therapy need,
• clinician and patient familiarity with budesonide ICS dosing,
• established payer inclusion (until pricing pressure removes incentives).

What are the main headwinds?

Key headwinds for Pulmicort Flexhaler (as a product rather than a molecule) are:

• generic substitution for budesonide ICS in many settings,
• competitive device ecosystems and branded differentiation in ICS/LABA,
• formulary and step-therapy policies that prefer combination products for many patients.

---

Market projection: base-case revenue direction

What should be expected for an older branded ICS?

For a branded legacy ICS like Pulmicort Flexhaler, the most likely trajectory over a multi-year horizon is:

• modest volume erosion tied to generic penetration and switching,
• pricing pressure through commercial and government reimbursement dynamics,
• partial stabilization where formularies protect specific device-based options or where substitution is constrained by prescriber/patient preference.

Scenario framework (directional, use for modeling)

A practical projection for Pulmicort Flexhaler should be modeled with three levers:

1. Net price (rebates, copay structures, payer mix)
2. Volume (new starts, switching, persistence)
3. Channel mix (commercial vs Medicare Part D vs Medicaid)

Base case typically assumes:

• continued generic pressure,
• stable or slightly declining persistence,
• gradual shift of eligible patients to ICS/LABA as clinical control improves or as formularies encourage combination use.

---

Competitive landscape: what steals share

ICS monotherapy competition

Budesonide ICS brands face competition from:

• other ICS molecules (fluticasone, mometasone, ciclesonide),
• multiple generic ICS entries,
• device-level usability advantages for competing inhalers.

ICS/LABA competition

The most significant share migration risk is from:

• ICS/LABA combinations for patients not well controlled on ICS alone,
• guideline-aligned escalation strategies that favor combination controller therapy earlier in treatment.

---

Regulatory and IP posture: what it implies for the future

How IP generally shapes this product category

Pulmicort Flexhaler’s active ingredient is long-established. That typically means:

• little forward-looking exclusivity value at the molecule level,
• commercial life depends on device-level differentiation, manufacturing/branding, and channel access rather than new IP.

---

Commercial watchlist: metrics to track for validation

For a product like Pulmicort Flexhaler, the actionable metrics that confirm whether the model is correct are:

• Formulary inclusion vs restriction (plan-level changes that affect copays and prior authorization)
• Generic share penetration in budesonide ICS classes
• ICS to ICS/LABA switching rates within asthma controller cohorts
• Persistence and refill intervals in claims datasets (device usability impact)
• Exacerbation-driven step-up therapy frequency (controls whether patients remain on ICS monotherapy)

---

Key Takeaways

• Pulmicort Flexhaler is an established budesonide ICS; current development activity is not dominated by new late-stage registrational programs for the product specifically.
• Commercial dynamics are driven by generic substitution, formulary access, and ongoing migration from ICS monotherapy toward ICS/LABA controllers.
• Base-case market projections for an older branded ICS generally show modest volume erosion plus pricing pressure, with stabilization only where device-specific access and patient persistence limit substitution.

---

FAQs

1) Is Pulmicort Flexhaler currently in late-stage clinical development?

Publicly disclosed, label-relevant late-stage development for Pulmicort Flexhaler itself is not evident in major registries in the current cycle.

2) What clinical endpoints typically support budesonide ICS positioning?

FEV1 and lung function, symptom and rescue use control, exacerbation reduction, and safety outcomes such as oral candidiasis and dysphonia.

3) What most affects market share for Pulmicort Flexhaler?

Generic penetration for budesonide ICS, payer formulary and step therapy policies, and patient switching to ICS/LABA combinations.

4) What would improve the outlook for Pulmicort Flexhaler?

Stronger payer/formulary protection for the device, improved adherence and persistence in claims data, or reduced switching to combination therapy in real-world cohorts.

5) What signals would indicate the projection is wrong?

Rapid payer restriction changes that accelerate substitution, or conversely higher-than-expected persistence and slower switching to ICS/LABA than modeled.

---

References

[1] U.S. Food and Drug Administration. Pulmicort Flexhaler prescribing information. FDA label database.
[2] ClinicalTrials.gov. Search results for “Pulmicort Flexhaler” and “budesonide dry powder inhaler” (last accessed current date).
[3] Global Initiative for Asthma (GINA). Asthma management and prevention guideline (most recent edition available at publication time).
[4] U.S. Department of Health and Human Services. Centers for Medicare & Medicaid Services. Part D and formulary reimbursement context for inhalation therapies (program materials).